These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

602 related articles for article (PubMed ID: 28825683)

  • 1. Towards a Better Understanding of GABAergic Remodeling in Alzheimer's Disease.
    Govindpani K; Calvo-Flores Guzmán B; Vinnakota C; Waldvogel HJ; Faull RL; Kwakowsky A
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28825683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The GABAergic system as a therapeutic target for Alzheimer's disease.
    Calvo-Flores Guzmán B; Vinnakota C; Govindpani K; Waldvogel HJ; Faull RLM; Kwakowsky A
    J Neurochem; 2018 Sep; 146(6):649-669. PubMed ID: 29645219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased GABAergic development in iPSC-derived neurons from patients with sporadic Alzheimer's disease.
    Tang Y; Han Y; Yu H; Zhang B; Li G
    Neurosci Lett; 2020 Sep; 735():135208. PubMed ID: 32615251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GABAergic dysfunction in excitatory and inhibitory (E/I) imbalance drives the pathogenesis of Alzheimer's disease.
    Bi D; Wen L; Wu Z; Shen Y
    Alzheimers Dement; 2020 Sep; 16(9):1312-1329. PubMed ID: 32543726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unsupervised excitation: GABAergic dysfunctions in Alzheimer's disease.
    Ambrad Giovannetti E; Fuhrmann M
    Brain Res; 2019 Mar; 1707():216-226. PubMed ID: 30503351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Options in Alzheimer´s Disease: The GABA Story.
    Solas M; Puerta E; Ramirez MJ
    Curr Pharm Des; 2015; 21(34):4960-71. PubMed ID: 26365140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GABAergic Microcircuits in Alzheimer's Disease Models.
    Villette V; Dutar P
    Curr Alzheimer Res; 2017; 14(1):30-39. PubMed ID: 27539596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired Expression of GABA Signaling Components in the Alzheimer's Disease Middle Temporal Gyrus.
    Govindpani K; Turner C; Waldvogel HJ; Faull RLM; Kwakowsky A
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33218044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia.
    Lanctôt KL; Herrmann N; Mazzotta P; Khan LR; Ingber N
    Can J Psychiatry; 2004 Jul; 49(7):439-53. PubMed ID: 15362248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurotransmitter-stimulated neuron-derived sEVs have opposite effects on amyloid β-induced neuronal damage.
    Dou Y; Xie J; Tan Y; Zhang M; Zhao Y; Liu X
    J Nanobiotechnology; 2021 Oct; 19(1):324. PubMed ID: 34654438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex- and age-specific modulation of brain GABA levels in a mouse model of Alzheimer's disease.
    Roy U; Stute L; Höfling C; Hartlage-Rübsamen M; Matysik J; Roβner S; Alia A
    Neurobiol Aging; 2018 Feb; 62():168-179. PubMed ID: 29154037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease.
    Garcia-Alloza M; Tsang SW; Gil-Bea FJ; Francis PT; Lai MK; Marcos B; Chen CP; Ramirez MJ
    Neurobiol Aging; 2006 Aug; 27(8):1110-7. PubMed ID: 15996794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GABAergic drugs and Alzheimer's disease.
    Limon A; Reyes-Ruiz JM; Miledi R
    Future Med Chem; 2011 Feb; 3(2):149-53. PubMed ID: 21428809
    [No Abstract]   [Full Text] [Related]  

  • 14. GABA(A) receptors in aging and Alzheimer's disease.
    Rissman RA; De Blas AL; Armstrong DM
    J Neurochem; 2007 Nov; 103(4):1285-92. PubMed ID: 17714455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GABAergic dysfunction, neural network hyperactivity and memory impairments in human aging and Alzheimer's disease.
    Jiménez-Balado J; Eich TS
    Semin Cell Dev Biol; 2021 Aug; 116():146-159. PubMed ID: 33573856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The GABAergic system in Alzheimer's disease: a systematic review with meta-analysis.
    Carello-Collar G; Bellaver B; Ferreira PCL; Ferrari-Souza JP; Ramos VG; Therriault J; Tissot C; De Bastiani MA; Soares C; Pascoal TA; Rosa-Neto P; Souza DO; Zimmer ER
    Mol Psychiatry; 2023 Dec; 28(12):5025-5036. PubMed ID: 37419974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebellin 4, a synaptic protein, enhances inhibitory activity and resistance of neurons to amyloid-β toxicity.
    Chacón PJ; del Marco Á; Arévalo Á; Domínguez-Giménez P; García-Segura LM; Rodríguez-Tébar A
    Neurobiol Aging; 2015 Feb; 36(2):1057-71. PubMed ID: 25534236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basic developmental rules and their implications for epilepsy in the immature brain.
    Ben-Ari Y
    Epileptic Disord; 2006 Jun; 8(2):91-102. PubMed ID: 16793570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutamate and GABA in Microglia-Neuron Cross-Talk in Alzheimer's Disease.
    Czapski GA; Strosznajder JB
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The GABAergic septohippocampal connection is impaired in a mouse model of tauopathy.
    Soler H; Dorca-Arévalo J; González M; Rubio SE; Ávila J; Soriano E; Pascual M
    Neurobiol Aging; 2017 Jan; 49():40-51. PubMed ID: 27743524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.